Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Abstract A134: Predicting activity of IMM-1-104 as single agent and in combination for patients with RAS or RAF mutant tumors

Praveen Nair, Sarah Kolitz, Jason Funt, Jan de Jong, Peter King, Amy Yamamura, Mai Johnson, Jenny Zhang, Kevin D Fowler, Anna Travesa, Amy Axel, Chris Walker, Scott Barrett, Benjamin J Zeskind, Brett Hall

Mol Cancer Ther (2023) 22 (12_Supplement): A134.

https://doi.org/10.1158/1535-7163.TARG-23-A134

Published: 01 December 2023

View article titled, Abstract A134: Predicting activity of IMM-1-104 as single agent and in combination for patients with RAS or RAF mutant tumors

Journal Articles

Abstract A093: Deep Cyclic Inhibition of the MAPK pathway with IMM-6-415, alone and in combination with encorafenib, demonstrates anti-tumor activity and tolerability in RAF mutant tumors in vivo

Anna Travesa, Mai Johnson, Peter King, Praveen Nair, Jason Funt, Sarah Kolitz, Kevin D Fowler, John Brothers II, Amy Axel, Scott Barrett, Benjamin J Zeskind, Brett Hall

Mol Cancer Ther (2023) 22 (12_Supplement): A093.

https://doi.org/10.1158/1535-7163.TARG-23-A093

Published: 01 December 2023

View article titled, Abstract A093: Deep Cyclic Inhibition of the MAPK pathway with IMM-6-415, alone and in combination with encorafenib, demonstrates anti-tumor activity and tolerability in RAF mutant tumors <em>in vivo</em>

Journal Articles

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

Jayaprakash D. Karkera, Gabriela Martinez Cardona, Katherine Bell, Dana Gaffney, Joseph C. Portale, Ademi Santiago-Walker, Christopher H. Moy, Peter King, Michael Sharp, Rastislav Bahleda, Feng R. Luo, John D. Alvarez, Matthew V. Lorenzi, Suso J. Platero

Mol Cancer Ther (2017) 16 (8): 1717–1726.

https://doi.org/10.1158/1535-7163.MCT-16-0518

Published: 02 August 2017

View article titled, Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

Includes: Supplementary data

Journal Articles

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

Mol Cancer Ther (2017) 16 (6): 1010–1020.

https://doi.org/10.1158/1535-7163.MCT-16-0589

Published: 01 June 2017

View article titled, Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

Includes: Supplementary data

Journal Articles

3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors

David Onion, Richard H. Argent, Alexander M. Reece-Smith, Madeleine L. Craze, Robert G. Pineda, Philip A. Clarke, Hari L. Ratan, Simon L. Parsons, Dileep N. Lobo, John P. Duffy, John C. Atherton, Andrew J. McKenzie, Rajendra Kumari, Peter King, Brett M. Hall, Anna M. Grabowska

Mol Cancer Ther (2016) 15 (4): 753–763.

https://doi.org/10.1158/1535-7163.MCT-15-0598

Published: 05 April 2016

View article titled, 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors

Includes: Supplementary data

Journal Articles

Abstract C12: Identification of predictive and pharmacodynamic biomarkers for an FGFR inhibitor.

Michael Sharp, Seth Sadis, Dan Rhodes, Neal Thompson, Marcus Otte, John Alvarez, Peter King, Hans Winkler, Suso Platero

Mol Cancer Ther (2011) 10 (11_Supplement): C12.

https://doi.org/10.1158/1535-7163.TARG-11-C12

Published: 12 November 2011

View article titled, Abstract C12: Identification of predictive and pharmacodynamic biomarkers for an FGFR inhibitor.

Journal Articles

Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models

Mol Cancer Ther (2011) 10 (9): 1542–1552.

https://doi.org/10.1158/1535-7163.MCT-11-0426

Published: 07 September 2011

View article titled, Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models

Includes: Supplementary data

Journal Articles

Abstract B111: Differential expression of c‐Met/HGF axis and epithelial‐mesenchymal transition (EMT)‐related gene markers between primary colorectal carcinomas and liver metastases in primary tissue, isolated cell types and in vivo

Richard H. Argent, Philip Clarke, Dileep N. Lobo, Kate Shepherd, Peter King, Brett Hall, Martin Page, Rajendra Kumari, Anna Grabowska, Susan A. Watson

Mol Cancer Ther (2009) 8 (12_Supplement): B111.

https://doi.org/10.1158/1535-7163.TARG-09-B111

Published: 10 December 2009

View article titled, Abstract B111: Differential expression of c‐Met/HGF axis and epithelial‐mesenchymal transition (EMT)‐related gene markers between primary colorectal carcinomas and liver metastases in primary tissue, isolated cell types and <em>in vivo</em>

Journal Articles

Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout

Matthias Versele, Willem Talloen, Cindy Rockx, Tamara Geerts, Boud Janssen, Tom Lavrijssen, Peter King, Hinrich W.H. Göhlmann, Martin Page, Tim Perera

Mol Cancer Ther (2009) 8 (7): 1846–1855.

https://doi.org/10.1158/1535-7163.MCT-08-1029

Published: 14 July 2009

View article titled, Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout

Includes: Supplementary data

Journal Articles

JNJ-26481585, a novel “second-generation” oral pan-histone deacetylase (HDAC) inhibitor, shows broad-spectrum preclinical antitumoral activity against solid and hematological malignancies

Janine Arts, Ann Marien, Peter King, Wim Floren, Ann Belien, Lut Janssen, Isabelle Pilatte, Bruno Roux, Laurence Decrane, Ron Gilissen, Luc Andries, Manfred Jung, Marc Jardin, Michel Janicot, Kristof Emelen, Patrick Angibaud

Mol Cancer Ther (2007) 6 (11_Supplement): A264.

Published: 01 November 2007

View article titled, JNJ-26481585, a novel “second-generation” oral pan-histone deacetylase (HDAC) inhibitor, shows broad-spectrum preclinical antitumoral activity against solid and hematological malignancies

Journal Articles

Real-time gene expression analysis in human xenografts for evaluation of histone deacetylase inhibitors

Ann Beliën, Stefanie De Schepper, Wim Floren, Boud Janssens, Ann Mariën, Peter King, Jacky Van Dun, Luc Andries, Jan Voeten, Luc Bijnens, Michel Janicot, Janine Arts

Mol Cancer Ther (2006) 5 (9): 2317–2323.

https://doi.org/10.1158/1535-7163.MCT-06-0112

Published: 19 September 2006

View article titled, Real-time gene expression analysis in human xenografts for evaluation of histone deacetylase inhibitors

NARROW

Abstract A134: Predicting activity of IMM-1-104 as single agent and in combination for patients with RAS or RAF mutant tumors

Abstract A093: Deep Cyclic Inhibition of the MAPK pathway with IMM-6-415, alone and in combination with encorafenib, demonstrates anti-tumor activity and tolerability in RAF mutant tumors in vivo

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors

Abstract C12: Identification of predictive and pharmacodynamic biomarkers for an FGFR inhibitor.

Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models

Abstract B111: Differential expression of c‐Met/HGF axis and epithelial‐mesenchymal transition (EMT)‐related gene markers between primary colorectal carcinomas and liver metastases in primary tissue, isolated cell types and in vivo

Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout

JNJ-26481585, a novel “second-generation” oral pan-histone deacetylase (HDAC) inhibitor, shows broad-spectrum preclinical antitumoral activity against solid and hematological malignancies

Real-time gene expression analysis in human xenografts for evaluation of histone deacetylase inhibitors

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only